NCT07400523 2026-04-17
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
Clinical Trials
7 trialsNCT06440967 2026-04-06
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT05879926 2026-04-02
OFSET
NRG Oncology
Phase 3 Recruiting
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT02003209 2025-08-08
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting